PDCD1 and liver cancer: After the initiation of programmed cell death-1 (PD-1) inhibitor therapy, the patients with decreased levels of serum-specific tumor markers (SSTMs) had significantly better OS and PFS than those with increased levels of SSTMs, and AFP was used in five cases of liver cancer [30].